Company Information - The company's registered address was changed from "No. 4299, Jindu Road, Minhang District, Shanghai" to "No. 66, Lane 133, Guangzhong Road, Minhang District, Shanghai" in March 2020[9] - The company's legal representative is Gu Kang[9] - The company's website is https://www.aohua.com and the email address is ir@aohua.com[9] - The company's foreign name is SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD. and its abbreviation is AOHUA ENDOSCOPE[9] - The company's Chinese name is 上海澳华内镜股份有限公司 and its Chinese abbreviation is 澳华内镜[9] - The company's registered address is No. 66, Lane 133, Guangzhong Road, Minhang District, Shanghai[9] - The company's office address is No. 66, Lane 133, Guangzhong Road, Minhang District, Shanghai with a postal code of 201108[9] - The company's registered address was changed from "Oriental Economic City, Luhui Town, Minhang District, Shanghai" to "No. 4299, Jindu Road, Minhang District, Shanghai" in July 2002[9] - The company's foreign name and abbreviation are SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD. and AOHUA ENDOSCOPE respectively[9] - The company's Chinese name and abbreviation are 上海澳华内镜股份有限公司 and 澳华内镜 respectively[9] Financial Performance - Revenue for the first half of 2024 increased by 22.29% year-on-year to RMB 353.52 million, driven by product promotion and brand influence[13][15] - Net profit attributable to shareholders decreased by 85.13% year-on-year to RMB 5.66 million, mainly due to restricted stock incentive plans and increased human resource investment[13][15] - Adjusted net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by 104.55% year-on-year to RMB -1.35 million[13][15] - Total assets as of the end of the reporting period increased by 2.84% to RMB 1.64 billion, while shareholders' equity increased by 1.15% to RMB 1.40 billion[13][15] - Basic earnings per share decreased by 86.21% year-on-year to RMB 0.04, and diluted earnings per share decreased by 85.71% to RMB 0.04[14] - R&D expenditure as a percentage of revenue increased by 0.62 percentage points to 24.70%[14] - Non-recurring gains and losses amounted to RMB 7.01 million, including government subsidies of RMB 1.51 million and gains from financial assets of RMB 6.67 million[16][17] - Revenue increased by 22.29% to RMB 353,524,229.81, driven by increased R&D investment and improved product quality[49] - Operating costs rose by 21.93% to RMB 100,909,672.24, in line with revenue growth[49] - Sales expenses surged by 44.93% to RMB 122,623,118.18 due to higher employee compensation, travel expenses, and market sample depreciation[49] - R&D expenses grew by 25.48% to RMB 87,336,827.97, primarily due to increased employee compensation and travel costs[49] - Net cash flow from operating activities decreased significantly to RMB -129,061,317.87, mainly due to slower collections and increased investments[49] - Net cash flow from investing activities dropped by 90.90% to RMB 1,902,414.62, as the company redeemed fewer financial products compared to the previous year[49] - Monetary funds decreased by 40.45% to RMB 145,629,546.22, accounting for 8.88% of total assets, due to expansion-related expenditures[50] - Accounts receivable increased by 47.16% to RMB 283,366,389.40, reflecting sales growth and slower collections[51] - Overseas assets amounted to RMB 53,861,515.22, representing 3.28% of total assets[52] - The company's investment in fixed-income financial assets, including structured deposits and negotiable certificates of deposit, totaled RMB 244,508,815.27 at the end of the reporting period[56] - Total operating income for the first half of 2024 reached 353,524,229.81 RMB, a 22.3% increase compared to 289,084,742.53 RMB in the same period of 2023[118] - Operating costs for the first half of 2024 were 371,843,932.97 RMB, a 33.8% increase from 277,959,752.83 RMB in the first half of 2023[118] - R&D expenses for the first half of 2024 amounted to 87,336,827.97 RMB, a 25.5% increase compared to 69,601,485.15 RMB in the same period of 2023[119] - Net profit attributable to the parent company's shareholders for the first half of 2024 was 5,661,627.44 RMB, a decrease of 85.1% from 38,079,363.05 RMB in the first half of 2023[119] - Total liabilities as of the first half of 2024 were 232,830,899.32 RMB, a 38.6% increase from 168,015,854.10 RMB in the same period of 2023[117] - Total equity attributable to the parent company's shareholders as of the first half of 2024 was 1,374,528,177.94 RMB, a 1.9% increase from 1,348,891,384.29 RMB in the first half of 2023[117] - Sales expenses for the first half of 2024 were 122,623,118.18 RMB, a 44.9% increase compared to 84,607,819.25 RMB in the same period of 2023[118] - Basic earnings per share for the first half of 2024 were 0.04 RMB, a significant decrease from 0.29 RMB in the first half of 2023[120] - Total comprehensive income for the first half of 2024 was 4,162,251.56 RMB, an 89.8% decrease from 40,942,548.84 RMB in the same period of 2023[120] - Parent company's operating income for the first half of 2024 was 327,110,897.35 RMB, a 23.7% increase compared to 264,517,499.10 RMB in the first half of 2023[121] - Net profit for the first half of 2024 was RMB 12,507,606.15, a decrease of 65.8% compared to RMB 36,614,609.92 in the same period last year[122] - Operating cash flow for the first half of 2024 was negative RMB 129,061,317.87, compared to negative RMB 29,789,202.51 in the same period last year[124] - Investment cash flow for the first half of 2024 was positive RMB 1,902,414.62, a significant decrease from RMB 20,901,953.83 in the same period last year[125] - Financing cash flow for the first half of 2024 was positive RMB 11,071,337.97, slightly higher than RMB 9,396,888.63 in the same period last year[125] - Cash and cash equivalents at the end of the first half of 2024 were RMB 128,628,546.22, a decrease of 47.4% compared to RMB 231,495,511.27 at the end of the same period last year[126] - Revenue from sales of goods and services in the first half of 2024 was RMB 293,879,912.37, a 1.7% increase compared to RMB 288,984,899.10 in the same period last year[124] - Cash paid for goods and services in the first half of 2024 was RMB 164,398,131.92, a 20.3% increase compared to RMB 136,642,183.22 in the same period last year[124] - Cash paid to employees in the first half of 2024 was RMB 172,023,158.69, a 38.7% increase compared to RMB 124,059,276.87 in the same period last year[125] - Cash received from investments in the first half of 2024 was RMB 263,500,000.00, a 34.6% decrease compared to RMB 402,919,396.79 in the same period last year[125] - Cash paid for investments in the first half of 2024 was RMB 170,500,000.00, a 42.9% decrease compared to RMB 298,800,000.00 in the same period last year[125] - Operating cash flow for the first half of 2024 was -102.79 million yuan, a significant decrease compared to 11.29 million yuan in the same period of 2023[127] - Sales revenue from goods and services in the first half of 2024 was 260.72 million yuan, a 5% increase from 248.27 million yuan in the same period of 2023[127] - Investment cash inflow in the first half of 2024 was 290.78 million yuan, a decrease of 12% from 330.51 million yuan in the same period of 2023[127][128] - Cash outflow for investment activities in the first half of 2024 was 259.64 million yuan, a decrease of 28% from 360.22 million yuan in the same period of 2023[128] - Net cash flow from financing activities in the first half of 2024 was 12.22 million yuan, a slight increase from 11.42 million yuan in the same period of 2023[128] - Total owner's equity at the end of the first half of 2024 was 1.41 billion yuan, an increase of 1.1% from 1.40 billion yuan at the beginning of the period[130][131] - Comprehensive income for the first half of 2024 was 4.25 million yuan, a decrease of 53% from 9.02 million yuan in the same period of 2023[130] - Cash and cash equivalents at the end of the first half of 2024 were 137.26 million yuan, a decrease of 30% from 196.33 million yuan at the beginning of the period[128] - The company's total owner's equity at the end of the period was 1,347,542,471.85 yuan, reflecting an increase from the previous period[133] - The comprehensive income for the period amounted to 41,275,629.09 yuan, contributing significantly to the owner's equity[132] - Owner's equity increased by 66,181,509.92 yuan during the period, driven by capital injections and retained earnings[132] - The company's capital reserve increased by 24,290,880.83 yuan, indicating strong capital accumulation[132] - The undistributed profit rose by 38,079,363.05 yuan, reflecting improved profitability[132] - The company's total owner's equity at the end of the period was 1,374,528,177.94 yuan, showing a steady growth trend[134] - The company's capital reserve increased by 52,951,112.50 yuan, indicating continued capital strengthening[134] - The undistributed profit decreased by 27,868,568.85 yuan, reflecting profit distribution to shareholders[134] - The company's total owner's equity at the end of the period was 1,333,957,614.28 yuan, showing a slight decrease from the previous period[133] - The company's capital reserve increased by 2,225,007.28 yuan, indicating continued capital accumulation[133] - The company's total owner's equity at the end of the period was RMB 1,286,557,886.91, with a capital reserve of RMB 1,042,246,884.40 and undistributed profits of RMB 103,524,011.64[136] - The company issued 615,000 restricted shares under the 2022 Restricted Stock Incentive Plan, with a total subscription amount of RMB 13,720,650.00, of which RMB 615,000.00 was recorded as share capital and RMB 13,105,650.00 as capital reserve[138] - The company's comprehensive income for the period was RMB 36,614,609.92, contributing to the increase in owner's equity[135] - The company's registered capital increased to RMB 133,955,000.00 after the issuance of restricted shares[138] - The company's owner's equity at the beginning of the period was RMB 1,225,535,596.81, with a capital reserve of RMB 1,018,454,204.22 and undistributed profits of RMB 66,909,401.72[135] - The company issued 78,000 restricted shares at an exercise price of RMB 22.31 per share, with a total subscription amount of RMB 1,740,180, increasing the company's share capital to RMB 134,033,000[139] - An additional 554,250 restricted shares were issued at the same exercise price of RMB 22.31 per share, further increasing the company's share capital to RMB 134,587,250[139] Market and Industry Overview - The global medical device market size reached $440 billion in 2020 and is expected to exceed $800 billion by 2030, with a CAGR of 6.3% from 2020 to 2030[19] - China's medical device market size increased from RMB 843.8 billion in 2021 to RMB 958.2 billion in 2022, with a 7-year CAGR of approximately 17.5%[19] - The global endoscope market size was approximately $26 billion in 2021, with a CAGR of 5.99% from 2017 to 2021[19] - China's endoscope market size is expected to reach RMB 60 billion by 2030, up from RMB 25 billion in 2021[19] - The global soft endoscope market size was approximately $8.98 billion in 2023 and is projected to grow to $16.73 billion by 2033[19] - China's soft endoscope market size increased to RMB 6.29 billion in 2021, with a YoY growth rate of 9.77%, and is expected to reach RMB 8.12 billion by 2025[19] Product and Technology Development - The company's AQ-300 ultra-high-definition endoscope system has entered the 4K field, providing high-quality and efficient platforms for endoscopic diagnosis and disease management[21] - The company's products have entered developed markets such as Germany, the UK, and South Korea, competing in the soft endoscope field dominated by foreign manufacturers[21] - The company's R&D investment in the first half of 2024 was RMB 87,336,827.97, a 25.48% increase compared to the same period last year[26][28] - The company added 3 new patent applications and was granted 14 invention patents in the first half of 2024[26][27] - The 4K ultra-high-definition flexible endoscope system project has a total investment of RMB 310,736,650, with RMB 40,376,464.60 invested in the current period and a cumulative investment of RMB 237,850,639.59[30] - The AQ-200 system upgrade and supporting development project has a total investment of RMB 48,858,800, with RMB 4,865,785.08 invested in the current period and a cumulative investment of RMB 36,733,985.41[30] - The 3D digestive endoscope development project has a total investment of RMB 22,036,000, with RMB 58,613.34 invested in the current period and a cumulative investment of RMB 14,011,135.85[30] - The endoscope robot system project has a total investment of RMB 104,500,000, with RMB 8,775,852.86 invested in the current period and a cumulative investment of RMB 55,641,242.36[30] - The supporting equipment development and other projects have a total investment of RMB 48,661,000, with RMB 7,045,001.78 invested in the current period and a cumulative investment of RMB 46,568,437.70[30] - The endoscope consumables product research and development project has a total investment of RMB 59,236,000, with RMB 4,225,604.40 invested in the current period and a cumulative investment of RMB 38,064,630.77[30] - The company's R&D investment accounted for 24.70% of operating revenue, an increase of 0.62 percentage points compared to the same period last year[28] - The company achieved a revenue of 353.52 million yuan in the first half of 2024, a year-on-year increase of 22.29%, with a net profit attributable to shareholders of 5.66 million yuan[40] - R&D investment in the first half of 2024 reached 87.34 million yuan, accounting for 24.70% of revenue, a year-on-year increase of 25.48%[40] - The company has 268 R&D personnel, accounting for 21.46% of the total workforce, with an average salary of 15.07 thousand yuan[33] - The company launched new products including electronic percutaneous cholangioscope and electronic cystoscope in March 2024, expanding into hepatobiliary surgery and urology fields[40] - In May 2024, the company released an electronic ureterorenoscope with an ultra-thin diameter for treating urinary stones[40] - The company has established 15 marketing branches and 34 service outlets nationwide, enhancing market coverage and competitiveness[40] - The company's R&D team includes 5 PhD holders, 87 master's degree holders, and 147 bachelor's degree holders, with 99 employees under 30 years old[33] - The company's AQ-100 and AQ-200 series products were listed in the Excellent Domestic Medical Equipment Catalog by the China Medical Equipment Association[34] - The company has obtained 240 patents, including 73 invention patents, 101 utility model patents, and 66 design patents

证券代码：688212 证券简称：澳华内镜 公告编号：2024-035 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，苏州君联欣康创业投资合伙企业（有限合伙）（以下 简称"君联欣康"）持有上海澳华内镜股份有限公司（以下简称"公司"）3,506,335 股，占公司当时总股本的 2.62%。高燊有限公司（以下简称"高燊"）持有公司 股份 5,134,650 股，占公司当时总股本的 3.83%。君联欣康与高燊构成一致行动 人关系，合计持有公司股份 8,640,985 股，占公司当时总股本的 6.45%。 减持计划的实施结果情况 君联欣康和高燊拟通过集中竞价、大宗交易方式减持公司股份，合计减持不 超过 2,157,930 股，合计减持比例不超过公司当时总股本的 1.61%。其中，通 过集中竞价交易方式减持股份不超过公司当时股份总数的 1%，自减持计划披露 之日起 15 个交易日后的 3 个月内进行；通过大宗交易方式减持股份不超过公 司当时股份总数的 2%，自减持 ...

上海澳华内镜股份有限公司 简式权益变动报告书 上市公司名称：上海澳华内镜股份有限公司 股票简称：澳华内镜 股票代码：688212 股票上市地点：上海证券交易所 信息披露义务人一：北京君联益康股权投资合伙企业（有限合伙） 住所及通讯地址：北京市海淀区科学院南路2号1号楼16层1601室 信息披露义务人二：苏州君联欣康创业投资合伙企业（有限合伙） 住所及通讯地址：苏州市吴江区松陵镇迎宾大道333号25号楼 信息披露义务人三：高燊有限公司 住所及通讯地址：香港中环皇后大道中99号中环中心6113室 股份变动性质：股份减少、被动稀释 签署日期：2024年8月9日 1 信息披露义务人声明 一、本报告书依据《中华人民共和国公司法》、《中华人民共和国证券 法》、《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格 式准则第15号——权益变动报告书》及相关的法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定， 本报告书已全面披露信息披露义务人在上海澳华内镜股份有限公司中拥有权益 的股份变动情况。 四、截至本报告书签署 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2024-034 上海澳华内镜股份有限公司 关于持股 5%以上股东减持达到 1%且持股比例 降至 5%以下的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次权益变动属于股份减持及被动稀释，不触及要约收购。 ● 本次权益变动为持股5%以上非第一大股东减持及被动稀释，不会导致公司的控股 股东及实际控制人发生变化。 （一）主动减持变动情况 | 信息披 | 名称1 | 北京君联益康股权投资合伙企业（有限合伙） | | --- | --- | --- | | 露义务 | 注册地址 | 北京市海淀区科学院南路2号1号楼16层1601室 | | 人基本 信息 | 名称2 | | 苏州君联欣康创业投资合伙企业（有限合伙） | | | | | --- | --- | --- | --- | --- | --- | --- | | | 注册地址 | | 苏州市吴江区松陵镇迎宾大道333号25号楼 | | | | | | 名称3 | | 高燊有限公司 | ...

证券代码：688212 证券简称：澳华内镜 公告编号：2024-033 上海澳华内镜股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 本 次 减 持 计 划 实 施 前 ， Appalachian Mountains Limited （ 以 下 简 称 "Appalachian"）持有上海澳华内镜股份有限公司（以下简称"公司"）2,737,929 股，占公司总股本 2.0427%，其中无限售条件流通股 2,737,929 股； 减持计划的实施结果情况 Appalachian 拟通过集中竞价、大宗交易方式减持公司股份，合计减持不超 过 2,667,256 股，合计减持比例不超过公司总股本的 1.99%。其中，通过集中竞 价交易方式减持不超过 1,333,628 股，自减持计划公告披露之日起 3 个交易日后 的 3 个月内进行；通过大宗交易方式减持不超过 1,333,628 股，自减持计划公告 披露之日起 3 个交易日后的 3 个月内进行。App ...

Investment Rating - The report maintains an "Outperform the Market" rating for the company [27]. Core Insights - The company is a leading player in the domestic soft endoscope market, focusing on technological innovation and product upgrades to enhance its competitive edge. The flagship product AQ-300 has been launched, which is expected to drive growth and facilitate the replacement of imported products [29][32]. - The domestic market is the primary revenue source for the company, with significant growth anticipated as the AQ-300 product gains traction both domestically and internationally [51][70]. - The company has a strong R&D capability, with a focus on high-end products that have received regulatory approvals in overseas markets, positioning it well for future growth [29][32]. Summary by Sections Company Overview - The company has been dedicated to the development of endoscopic diagnostic instruments since its establishment in 1994, providing a complete solution that includes endoscopic devices and surgical consumables [40][68]. Competitive Advantages - The company has a notable R&D technology advantage, with continuous improvements in product offerings, including the AQ-300, which features advanced imaging and control technologies [29][32]. - The company has successfully penetrated international markets, including Germany, the UK, and South Korea, with its products [32]. Financial Performance - The company reported a revenue of 6.78 billion yuan in 2023, with a year-on-year growth of 52.3%. The revenue from endoscopic devices accounted for 91.8% of total revenue [70]. - The gross profit margin has been steadily increasing, reaching 76.4% in Q1 2024, driven by the growing sales of high-end products [53][73]. Future Outlook - The company projects significant revenue growth, with forecasts of 9.91 billion yuan in 2024, 14.44 billion yuan in 2025, and 20.18 billion yuan in 2026, reflecting a compound annual growth rate (CAGR) of 46.2% [38][77]. - The management's confidence in achieving these targets is underscored by the recent stock incentive plans aimed at motivating key personnel [56][77].

证券代码：688212 证券简称：澳华内镜 公告编号：2024-032 上海澳华内镜股份有限公司 2024 年第一次临时股东大会决议公告 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 07 月 16 日 （二） 股东大会召开的地点：上海市闵行区光中路 133 弄 66 号澳华内镜大厦十 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 69 | | --- | --- | | 普通股股东人数 | 69 | | 2、出席会议的股东所持有的表决权数量 | 47,247,609 | | 普通股股东所持有表决权数量 | 47,247,609 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 35.1055 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 35.1055 | | （%） | | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次会议由公司董事会召集，董事长顾康先生主持。会议采用现场投票和网 络投票相结合的方式 ...

上海市通力律师事务所关于上海澳华内镜股份有限公司 2024 年第一次临时股东大会的法律意见书 深圳 SHENZHEN 香港 HONG KONG 伦敦 LONDON 致:上海澳华内镜股份有限公司 上海市通力律师事务所(以下简称"本所")接受上海澳华内镜股份有限公司(以 下简称"公司"）的委托,指派本所夏青律师、说钰律师(以下简称"本所律师")根 据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东大会规则》等 法律法规和规范性文件(以下统称"法律法规")及《上海澳华内镜股份有限公司章程》 (以下简称"公司章程")的规定就公司 2024 年第一次临时股东大会(以下简称"本 次股东大会")相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以 了核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中 的所有签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、 完整和有效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会 人员资格和召集人资格及表决程 ...

专家发言内容仅代表专家个人观点 本次会议内容不得涉及国家保密信息、内幕信息未公开重大信息、商业秘密、个人隐私不得涉及可能引发不当炒作或股价异常波动的敏感信息不得涉及影响社会或资本市场稳定的言论 未经华创证券事先书面许可任何机构或个人不得以任何形式复制刊载转载转发引用本次会议内容否则由此造成的一切后果及法律责任由该机构或个人承担本公司保留追究其法律责任的权利市场有风险投资需谨慎 各位投资人大家晚上好感谢大家来参加我们的设备更新系列电话会议今天是第五期我们今天也是非常荣幸的邀请到了奥华内静的董秘师总来跟大家做设备更新相关的一个分享设备更新我们之前也做过包括超声包括大型影像设备的一些专题的系列电话会这次内静其实也是本次的设备更新的重要的方向之一 所以今天我们请施总跟大家聊一下这个设备更新当然也包括澳华经济的一些基本面的情况那我这边首先是准备了一些大家也比较关心的问题跟施总做请教然后我们也会很快地放开投资人的提问 那首先我先拋砖引玉问施总几个小问题第一个就是大家比较关心的就是这次的设备更新大体会是一个多大的规模特别是落实到内径这个板块可能会带来一个多大的增量呢谢谢施总 这次设备更新总体的政策还处于落地的一个状态中也很 ...

| 2024 | 年第一次临时股东大会会议须知 2 | | --- | --- | | 2024 | 年第一次临时股东大会会议议程 4 | | 《关于使用部分超募资金永久补充流动资金的议案》 5 | | 1 二零二四年七月 上海澳华内镜股份有限公司 2024年第一次临时股东大会会议资料 上海澳华内镜股份有限公司 会议资料目录 上海澳华内镜股份有限公司 2024年第一次临时股东大会会议资料 证券简称：澳华内镜 证券代码：688212 上海澳华内镜股份有限公司 2024 年第一次临时股东大会 会议资料 上海澳华内镜股份有限公司 2024年第一次临时股东大会会议资料 2024 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、 中国证监会《上市公司股东大会规则》以及《上海澳华内镜股份有限公司章程》、 《上海澳华内镜股份有限公司股东大会议事规则》的相关规定，特制定 2024 年 第一次临时股东大会会议须知： 六、股东及股东代理人要求发言时，不得打断会议报告人的报告或其他股东 及股东代理人的发言，在股 ...